InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Price Performance

NYSE NSPR opened at $2.94 on Tuesday. The company has a fifty day moving average price of $2.57 and a 200-day moving average price of $2.62. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.42. The firm has a market cap of $76.68 million, a price-to-earnings ratio of -3.92 and a beta of 0.93.

InspireMD (NYSE:NSPR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The firm had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same quarter in the previous year, the business earned ($0.15) EPS. On average, research analysts anticipate that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NSPR. Affiance Financial LLC purchased a new position in InspireMD during the 3rd quarter valued at about $492,000. Parkman Healthcare Partners LLC bought a new position in InspireMD in the 3rd quarter worth about $279,000. Finally, Rosalind Advisors Inc. raised its holdings in shares of InspireMD by 266.4% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock valued at $6,272,000 after acquiring an additional 1,827,579 shares in the last quarter. 44.78% of the stock is owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.